Epimutation and cancer

A new carcinogenic mechanism of Lynch syndrome (Review)

Kouji Banno, Iori Kisu, Megumi Yanokura, Kosuke Tsuji, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Hiroyuki Nomura, Eiichirou Tominaga, Nobuyuki Susumu, Daisuke Aoki

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Epimutation is defined as abnormal transcriptional repression of active genes and/or abnormal activation of usually repressed genes caused by errors in epigenetic gene repression. Epimutation arises in somatic cells and the germline, and constitutional epimutation may also occur. Epimutation is the first step of tumorigenesis and can be a direct cause of carcinogenesis. Cancers associated with epimutation include Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC), chronic lymphocytic leukemia, breast cancer and ovarian cancer. Epimutation has been shown for many tumor suppressor genes, including RB, VHL, hMLH1, APC and BRCA1, in sporadic cancers. Methylation has recently been shown in DNA from normal tissues and peripheral blood in cases of sporadic colorectal cancer and many studies show constitutive epimutation in cancers. Epimutation of DNA mismatch repair (MMR) genes (BRCA1, hMLH1 and hMSH2) involved in development familial cancers has also been found. These results have led to a focus on epimutation as a novel oncogenic mechanism.

Original languageEnglish
Pages (from-to)793-797
Number of pages5
JournalInternational Journal of Oncology
Volume41
Issue number3
DOIs
Publication statusPublished - 2012 Sep

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Epigenetic Repression
Colorectal Neoplasms
Neoplasms
Carcinogenesis
BRCA1 Gene
Genes
DNA Mismatch Repair
B-Cell Chronic Lymphocytic Leukemia
Tumor Suppressor Genes
Ovarian Neoplasms
Methylation
Breast Neoplasms
DNA

Keywords

  • Epimutation
  • Epithelial cell adhesion molecule
  • Human MutL homologue 1
  • Human MutS homologue 2
  • Lynch syndrome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epimutation and cancer : A new carcinogenic mechanism of Lynch syndrome (Review). / Banno, Kouji; Kisu, Iori; Yanokura, Megumi; Tsuji, Kosuke; Masuda, Kenta; Ueki, Arisa; Kobayashi, Yusuke; Yamagami, Wataru; Nomura, Hiroyuki; Tominaga, Eiichirou; Susumu, Nobuyuki; Aoki, Daisuke.

In: International Journal of Oncology, Vol. 41, No. 3, 09.2012, p. 793-797.

Research output: Contribution to journalArticle

Banno, Kouji ; Kisu, Iori ; Yanokura, Megumi ; Tsuji, Kosuke ; Masuda, Kenta ; Ueki, Arisa ; Kobayashi, Yusuke ; Yamagami, Wataru ; Nomura, Hiroyuki ; Tominaga, Eiichirou ; Susumu, Nobuyuki ; Aoki, Daisuke. / Epimutation and cancer : A new carcinogenic mechanism of Lynch syndrome (Review). In: International Journal of Oncology. 2012 ; Vol. 41, No. 3. pp. 793-797.
@article{97903d4fe7334ee2accc7ee7d6ac7ffb,
title = "Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome (Review)",
abstract = "Epimutation is defined as abnormal transcriptional repression of active genes and/or abnormal activation of usually repressed genes caused by errors in epigenetic gene repression. Epimutation arises in somatic cells and the germline, and constitutional epimutation may also occur. Epimutation is the first step of tumorigenesis and can be a direct cause of carcinogenesis. Cancers associated with epimutation include Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC), chronic lymphocytic leukemia, breast cancer and ovarian cancer. Epimutation has been shown for many tumor suppressor genes, including RB, VHL, hMLH1, APC and BRCA1, in sporadic cancers. Methylation has recently been shown in DNA from normal tissues and peripheral blood in cases of sporadic colorectal cancer and many studies show constitutive epimutation in cancers. Epimutation of DNA mismatch repair (MMR) genes (BRCA1, hMLH1 and hMSH2) involved in development familial cancers has also been found. These results have led to a focus on epimutation as a novel oncogenic mechanism.",
keywords = "Epimutation, Epithelial cell adhesion molecule, Human MutL homologue 1, Human MutS homologue 2, Lynch syndrome",
author = "Kouji Banno and Iori Kisu and Megumi Yanokura and Kosuke Tsuji and Kenta Masuda and Arisa Ueki and Yusuke Kobayashi and Wataru Yamagami and Hiroyuki Nomura and Eiichirou Tominaga and Nobuyuki Susumu and Daisuke Aoki",
year = "2012",
month = "9",
doi = "10.3892/ijo.2012.1528",
language = "English",
volume = "41",
pages = "793--797",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Epimutation and cancer

T2 - A new carcinogenic mechanism of Lynch syndrome (Review)

AU - Banno, Kouji

AU - Kisu, Iori

AU - Yanokura, Megumi

AU - Tsuji, Kosuke

AU - Masuda, Kenta

AU - Ueki, Arisa

AU - Kobayashi, Yusuke

AU - Yamagami, Wataru

AU - Nomura, Hiroyuki

AU - Tominaga, Eiichirou

AU - Susumu, Nobuyuki

AU - Aoki, Daisuke

PY - 2012/9

Y1 - 2012/9

N2 - Epimutation is defined as abnormal transcriptional repression of active genes and/or abnormal activation of usually repressed genes caused by errors in epigenetic gene repression. Epimutation arises in somatic cells and the germline, and constitutional epimutation may also occur. Epimutation is the first step of tumorigenesis and can be a direct cause of carcinogenesis. Cancers associated with epimutation include Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC), chronic lymphocytic leukemia, breast cancer and ovarian cancer. Epimutation has been shown for many tumor suppressor genes, including RB, VHL, hMLH1, APC and BRCA1, in sporadic cancers. Methylation has recently been shown in DNA from normal tissues and peripheral blood in cases of sporadic colorectal cancer and many studies show constitutive epimutation in cancers. Epimutation of DNA mismatch repair (MMR) genes (BRCA1, hMLH1 and hMSH2) involved in development familial cancers has also been found. These results have led to a focus on epimutation as a novel oncogenic mechanism.

AB - Epimutation is defined as abnormal transcriptional repression of active genes and/or abnormal activation of usually repressed genes caused by errors in epigenetic gene repression. Epimutation arises in somatic cells and the germline, and constitutional epimutation may also occur. Epimutation is the first step of tumorigenesis and can be a direct cause of carcinogenesis. Cancers associated with epimutation include Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC), chronic lymphocytic leukemia, breast cancer and ovarian cancer. Epimutation has been shown for many tumor suppressor genes, including RB, VHL, hMLH1, APC and BRCA1, in sporadic cancers. Methylation has recently been shown in DNA from normal tissues and peripheral blood in cases of sporadic colorectal cancer and many studies show constitutive epimutation in cancers. Epimutation of DNA mismatch repair (MMR) genes (BRCA1, hMLH1 and hMSH2) involved in development familial cancers has also been found. These results have led to a focus on epimutation as a novel oncogenic mechanism.

KW - Epimutation

KW - Epithelial cell adhesion molecule

KW - Human MutL homologue 1

KW - Human MutS homologue 2

KW - Lynch syndrome

UR - http://www.scopus.com/inward/record.url?scp=84865007337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865007337&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1528

DO - 10.3892/ijo.2012.1528

M3 - Article

VL - 41

SP - 793

EP - 797

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -